We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathogen Molecular Diagnostics Evaluated for Routine Use

By LabMedica International staff writers
Posted on 24 Jun 2013
Molecular diagnosis of microbial etiologies using a universal polymerase chain reaction (PCR) and sequencing test has been evaluated in the daily routine of a diagnostic laboratory. More...


The identification of bacterial and fungal pathogens using the test has been analyzed in a privately operated diagnostics laboratory, including the interpretation of the data, and the experience in performing the PCR test.

Medical laboratory scientists from the Dr. Constance Brunner Laboratory (Konstanz, Germany) examined 96 specimens originating from 66 patients under suspect of infectious endocarditis, infections of joints, encephalitis/meningitis, systemic infections, and infections of unknown origin. Samples comprised cultured and noncultured blood, synovial fluid, synovial tissue, heart valves, pacemakers, spinal tissue, cerebrospinal fluid, and swabs.

The samples were analyzed by the SepsiTest (Molzym; Bremen, Germany) and compared to culture results. Primers specific for 16S ribosomal ribonucleic (rRNA) eubacterial sequences and primers, predominantly specific for Gram-positive microorganisms (GP) were used for amplification. A third PCR was included by routine, covering predominantly the Gram-negative bacteria (GN). Pan-fungal or 18S rRNA gene-specific PCR was done on explicit request only. The 16S primers used are included in the SepsiTest kit, but GP and GN primers were ordered separately from Molzym.

The SepsiTest PCR and culture were concordant in 26 negative and 8 positive cases. A group of 25 patients was culture-negative, but PCR-positive. In at least 14 of these, common and/or rare etiologies were identified, while for 4 patients the results of 16S PCR could not be unequivocally linked with the underlying disease. Another large group of 29 patients’ samples was discordant in PCR and culture results, including 25 PCR-positive, but culture-negative, and 4 were PCR-positive and culture-positive, but with the identification result being discordant from that obtained by PCR.

The authors concluded that despite the limitations imposed on its use such as costs, false positives due to environmental contamination, SepsiTest turned out to be a tool appropriate for the diagnosis of pathogens in the clinical routine. Nevertheless, as the results show, the test cannot replace but may rather complement culture diagnosis, especially as a tool for ultima-ratio analysis. The study was published on June 7, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Dr. Constance Brunner Laboratory
Molzym



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.